Equity | Fangda Partners

China Resources Microelectronics as sponsor’s PRC counsel on the IPO of CRM on the STAR Market in 2020, a milestone in the opening up of China’s domestic capital markets. CRM is the first foreign company to directly offer shares and list in the PRC, the first listed company in the PRC whose denomination currency is not the renminbi, the first foreign company to configure its corporate governance to closely align with A-share-listed companies, the first listed company to adopt a greenshoe provision in the Shanghai Stock Exchange STAR Market.
AMEC and ArcSoft as issuer’s PRC counsel on the A-share IPO on the STAR Market. This was at the time the largest valuation of new shares issued by the STAR Market.
Suzhou Zelgen Biopharmaceuticals as sponsor’s PRC counsel on the IPO of Zelgen on the STAR market in 2020. This was the first company to be listed without a track record of revenues and profits, as well as the first company listing on the STAR Market applying the fifth set of listing standards on the A-share market.
FII as sponsor’s PRC counsel on the IPO of Foxconn Industrial Internet Co. in 2018. This was then the largest A-share IPO by an industrial enterprise, the largest A-share IPO by a foreign-invested enterprise, the largest A-share IPO by a non-financial enterprise since 2010, and the largest A-share IPO since 2016.
Wuxi AppTec as issuer’s PRC counsel on the RMB2.3 billion A-share IPO on the Shanghai Stock Exchange, and as its PRC and Hong Kong counsel for its HK$7.5 billion IPO on the Hong Kong Stock Exchange. The listings followed a delisting from NASDAQ and a series of complicated restructuring to dismantle the original red-chip structure.
Mindray as issuer’s PRC counsel for the A-share IPO on the Shenzhen Stock Exchange in 2018, following its U.S. delisting in 2015 and a series of complicated restructurings to dismantle their original red-chip structure.
Huatai Securities, a PRC company listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, as issuer’s PRC counsel for its offering 82 million global depositary receipts (GDRs) under the Shanghai-London Stock Connect regime. This was the first GDR issuing of a Shanghai Stock Exchange-listed company under Shanghai-London Stock Connect.
Alibaba as issuer’s PRC counsel for its HK$88 billion IPO on the Hong Kong Stock Exchange. The global offering is the largest ever cross-border secondary offering and also the biggest equity offering on the Hong Kong Stock Exchange since 2010. The Firm also represented Alibaba Group in its historic US$25 billion initial public offering on NYSE in 2014, which was then the largest IPO ever conducted.
Budweiser Brewing Company APAC as issuer’s PRC counsel for its US$5bn IPO on the Hong Kong Stock Exchange. The global offering was the third-largest IPO globally in 2019.
BeiGene as issuer’s PRC counsel for its HK$7 billion IPO on the Hong Kong Stock Exchange. This was the first dual primary listing of a Nasdaq-listed biotech company.
Cstone Pharmaceuticals as PRC issuer’s counsel for its HK$2 billion IPO on the Hong Kong Stock Exchange.
Jinxin Fertility Group as issuer’s Hong Kong counsel on its approximately US$400 million listing.
China Kepei Education Group, as Hong Kong counsel of the joint sponsors and joint global coordinators, on the US$113 million global offering and initial public offering on the Main Board of the Hong Kong Stock Exchange.
Koolearn Technology Holding, as Hong Kong counsel of the sponsor and global coordinators, on its global offering on the Main Board of the Hong Kong Stock Exchange, raising US$200 million.
Frontage Holdings Corporation, as Hong Kong counsel of the joint sponsors and other joint global coordinators and underwriters, on its global initial public offering on the Main Board of the Hong Kong Stock Exchange, raising US$205 million.
Hua Medicine, as Hong Kong counsel of the joint sponsors and other joint global coordinators and underwriters, on the US$110 million global initial public offering on the Main Board of the Hong Kong Stock Exchange.